|
Match
|
Document |
Document Title |
|
|
8178510 |
Preparation of thioarabinofuranosyl compounds and use thereof
Patients suffering from cancer are treated by being administered a compound represented by the following formula: wherein each R individually is H or an aliphatic or aromatic acyl group;A is...
|
|
|
8178131 |
Pyrrolopyridines as kinase inhibitors
Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in...
|
|
|
8173620 |
BHQ-caged nucleotide probes photolysable by two-photon excitation
The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by...
|
|
|
8158605 |
Azacytidine analogues and uses thereof
The present invention is directed toward compounds of Formula (I) as follows: wherein, R is H, R5C(O);R1 is where the crossing dashed line illustrates the bond formed joining R1 to the molecule of...
|
|
|
8158606 |
β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is pr...
|
|
|
8143234 |
Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
The present invention provides methods of improving a cognitive function or a neurological function, treating or ameliorating a decline in a cognitive function or a neurological function,...
|
|
|
8129358 |
Substituted pyrazole and triazole compounds as KSP inhibitors
Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with...
|
|
|
8124593 |
Methods of treatment using sapacitabine
A first aspect of the invention relates to a method of treating leukaemia or myelodysplastic syndromes (MDS), said method comprising administering a therapeutically effective amount of...
|
|
|
8114854 |
Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.
|
|
|
8097595 |
Modulation of telomere length in telomerase positive cells and cancer therapy
Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention...
|
|
|
8076310 |
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated,...
|
|
|
8071567 |
4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication
The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to...
|
|
|
8066971 |
Targeting pulmonary epithelium using ADRP
This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The...
|
|
|
8067392 |
Compositions and methods for treatment of mitochondrial diseases
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien...
|
|
|
8067391 |
ODCase inhibitors for the treatment of malaria
The present invention includes methods of treating or preventing malaria by administering an anti-malarial effective amount of 6-substituted uridine derivatives to a subject need thereof. The...
|
|
|
8063025 |
Nucleoside prodrugs and uses thereof
Compounds having the formula I or II wherein R1, R2, B, and V are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV...
|
|
|
8058260 |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-...
|
|
|
8058261 |
3′-ethynylcytidine derivative
To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug. The invention provides a 3′-ethynylcytidine derivative r...
|
|
|
8044033 |
Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer
The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient....
|
|
|
8044034 |
Nanoparticle derivatives of gemcitabine
The use of squalenic acid or a derivative thereof in formulating at least one polar active principle with a molecular weight of 100 Da or more, in the form of nanoparticles, and pharmaceutical...
|
|
|
8030294 |
Compounds for the treatment of psychiatric or substance abuse disorders
The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or...
|
|
|
8022047 |
Combination anticancer agents
A cancer therapeutic agent comprising a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable...
|
|
|
8017594 |
Agent against psychosocial stresses
To provide a novel anti-psychosocial stress agent which is highly safety and can be continuously taken, more particularly, a novel anti-psychosocial stress agent which prevents or alleviates...
|
|
|
8008274 |
P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor...
|
|
|
7994143 |
Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a...
|
|
|
7989188 |
Conjugates for cancer therapy and diagnosis
The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In...
|
|
|
7985737 |
Compositions and methods for the regulation of homocysteine levels within the body
Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that...
|
|
|
7981445 |
Compositions and methods for preparation of poorly water soluble drugs with increased stability
The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The...
|
|
|
7977320 |
Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
The present invention provides compositions and methods for increasing the amount of active Syk protein kinase and or SHP-1 protein phosphatase in a cell. The compositions and methods are useful...
|
|
|
7968565 |
Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
The present invention relates to SNS-595 and methods of treating cancer using the same.
|
|
|
7968085 |
Hydrogel formulations
A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active...
|
|
|
7964580 |
Nucleoside phosphoramidate prodrugs
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt),...
|
|
|
7951788 |
Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
The present invention relates to the use of the compound according to formula (I) Where S is (A) or (B); X is H or F; R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate,...
|
|
|
7951787 |
Phosphoramidate compounds and methods of use
Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may...
|
|
|
7947661 |
Compounds for the treatment of marihuana dependence, withdrawal, and usage
The invention provides methods for treating or suppressing marihuana usage, withdrawal, or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or...
|
|
|
7935681 |
Antiviral nucleosides
4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3
-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed...
|
|
|
7932235 |
Triazolyl tropane derivatives
This invention relates to novel triazolyl tropane derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a...
|
|
|
7928086 |
β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is pr...
|
|
|
7915233 |
Compositions and methods for treatment of mitochondrial diseases
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien...
|
|
|
7915234 |
Pharmaceutically active uridine esters
The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R′ represents hydrogen or a h...
|
|
|
7897565 |
Compositions for HCV treatment
The present invention concerns a pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporine, e.g., a compound of formula I and b) a...
|
|
|
7897326 |
Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
Methods and compositions for reducing, preventing or reversing organ damage and/or enhancing organ preservation by administration of a peroxisome-proliferator activated receptor-alpha (PPARα) ...
|
|
|
7893037 |
Pharmaceutical composition and process
The present invention relates to a method of forming granules of (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,
4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate;...
|
|
|
7879816 |
Methods of treating cancer and other conditions or disease states using LFMAU and LDT
The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease...
|
|
|
7879815 |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to...
|
|
|
7863255 |
Methods of administering antitumor agent comprising deoxycytidine derivative
Antitumor treatment regimens comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyri
midinone, or a ...
|
|
|
7863254 |
Compounds for the treatment of psychiatric or substance abuse disorders
The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or...
|
|
|
7858594 |
Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, t...
|
|
|
7860552 |
CNS assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses
In general, the invention features methods for identifying therapeutic interventions for functional illnesses, e.g., neuropathic pain or depression, and methods for identifying markers for...
|
|
|
7851479 |
Use of pyrimidinedione derivative for preventing or treating hepatitis C
A pyrimidinedione derivative of formula (I) or a pharmaceutically acceptable salt thereof exhibits excellent inhibitory activity against hepatitis C virus.
|